Peer-reviewed publications, perspectives from our scientific team, and corporate news. Filter by category to explore the body of evidence behind the platform.
First-in-human Phase I data demonstrating safety and immunogenicity of SPYVLP01 in healthy adult volunteers — establishing the clinical foundation for our lead CMV program.
Following positive Phase I safety and immunogenicity data, the company prepares its lead asset for Phase II initiation, targeting congenital CMV prevention.
Second clinical-stage asset advances to first-in-human readiness, addressing the EBV–multiple sclerosis causal link increasingly recognised in the literature.
Platform validation across multiple WHO priority pathogens — swap-in modularity demonstrated in non-human primate models.
How the irreversible isopeptide bond changes the immunology equation — and why so many other display chemistries fall short in vivo.
First demonstration that SpyCatcher-modified hexons enable covalent surface decoration while evading anti-vector immunity.
Foundational paper detailing the design principles behind SpyVLP architecture and immunological performance vs. conventional VLPs.
An accessible explainer of why congenital CMV is a public-health priority and how multivalent VLP design can address it.
Veteran vaccine clinician joins to drive the clinical advancement of SpyVLP across CMV, EBV and pandemic-preparedness programs.
Inside the molecular engineering that produced a covalent adenoviral surface — and the unexpected consequences for anti-vector immunity.
Capital extends runway through Phase II readout for SPYVLP01 and accelerates SpyVector platform development.
A walk through the formulation work that made our VLPs stable enough for global deployment without ultra-cold logistics.
No items in this category yet.